Ozempic promotes weight loss by mimicking the GLP-1 hormone the body naturally produces after eating, so users feel fuller ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

While President-elect Donald Trump looks poised to scrap many policies of the Biden administration, one veteran analyst says ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

B&D Nutritional Ingredients, Inc., a raw material distributor in the dietary supplement industry and exclusive U.S. distribution partner to CarnoSyn ® Brands and Natural Alternatives International, ...

Participants in Wegovy clinical trials were more likely to report “severe gastrointestinal adverse reactions,” the FDA's ...

Antag Therapeutics thinks its glucose dependent insulinotropic polypeptide receptor (GIPR) antagonist could carve out a space ...

GLP-1 receptor agonists, like Ozempic and Wegovy, have been everywhere over the past few years, and research seems to be ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class ...